Loading...
1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data
BACKGROUND: Despite the advantageous spectrum of activity of itraconazole, it is rarely used as a prophylactic agent due to limited bioavailability and intolerance of the conventional formulation. After the development of a novel formulation SUBA-itraconazole® (SUper BioAvailability), we undertook a...
Na minha lista:
| Udgivet i: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255503/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.972 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|